COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

December 8, 2022

https://www.globenewswire.com/news-release/2022/12/08/2569941/0/en/COMP360-psilocybin-therapy-shows-potential-in-open-label-study-in-type-II-bipolar-disorder-presented-at-ACNP.html

12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II bipolar disorder

Read more at globenewswire.com

Related news for (CMPS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.